-
公开(公告)号：EP2646020B1
公开(公告)日：2016-09-21
申请号：EP11844228.4
申请日：2011-11-30
申请人： GlaxoSmithKline LLC
发明人： KNIGHT, Steven, David , MILLER, William, Henry , NEWLANDER, Kenneth, Allen , VERMA, Sharad, Kumar
IPC分类号： C07D401/12 , C07D401/14 , C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/506 , A61P35/00
CPC分类号： C07D401/12 , C07D401/14 , C07D417/14
-
公开(公告)号：EP3221312A2
公开(公告)日：2017-09-27
申请号：EP15861618.5
申请日：2015-11-19
申请人： GlaxoSmithKline LLC
发明人： BLUM, Charles A. , CALDWELL, Richard Dana , CASAUBON, Rebecca , DISCH, Jeremy S. , FOX, Ryan Michael , KOPPETSCH, Karsten , MILLER, William, Henry , NG, Pui, Yee , OALMANN, Christopher , PERNI, Robert, B. , SZCZEPANKIEWICZ, Bruce G. , WHITE, Brian H.
IPC分类号： C07D471/04 , C07D513/18
CPC分类号： C07D471/18 , A61K31/4995 , A61K31/506 , A61K31/551 , A61K45/06 , A61P17/10 , C07D487/04 , C07D513/18 , C07D519/00
摘要： The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
摘要翻译： 本发明涉及新的取代的桥联脲化合物，相应的类似物，药物组合物及其使用方法。 本发明的瑟土因调节性化合物可以用于增加细胞的寿命，并且治疗和/或预防各种各样的疾病和病症，包括但不限于例如与以下疾病或病症有关的疾病或病症 衰老或压力，糖尿病，肥胖症，神经退行性疾病，心血管疾病，凝血障碍，炎症，癌症和/或潮红以及将受益于线粒体活性增加的疾病或病症。 本发明还涉及包含沉默调节蛋白调节化合物与另一种治疗剂组合的组合物。
-
公开(公告)号：EP2931707A1
公开(公告)日：2015-10-21
申请号：EP13870106.5
申请日：2013-12-12
申请人： Glaxosmithkline LLC
发明人： KNIGHT, Steven, David , MILLER, William, Henry , NEWLANDER, Kenneth, Allen , DONATELLI, Carla, A.
IPC分类号： C07D213/56
CPC分类号： C07D405/14 , C07D213/68 , C07D213/73 , C07D309/38 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12
摘要： This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. Epigenetic modifications play an important role in the regulation of many cellular processes including cell proliferation, differentiation, and cell survival. Global epigenetic modifications are common in cancer, and include global changes in DNA and/or histone methylation, dysregulation of non-coding RNAs and nucleosome remodeling leading to aberrant activation or inactivation of oncogenes, tumor suppressors and signaling pathways.
-
公开(公告)号：EP2646020A1
公开(公告)日：2013-10-09
申请号：EP11844228.4
申请日：2011-11-30
申请人： GlaxoSmithKline LLC
发明人： KNIGHT, Steven, David , MILLER, William, Henry , NEWLANDER, Kenneth, Allen , VERMA, Sharad, Kumar
IPC分类号： A61K31/404
CPC分类号： C07D401/12 , C07D401/14 , C07D417/14
摘要： Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
摘要翻译： 本文公开了式（I）的azaindazoles，其中各种基团如本文所定义，并且可用于治疗癌症。
-
公开(公告)号：EP1560821B1
公开(公告)日：2010-03-24
申请号：EP03816120.4
申请日：2003-11-04
申请人： GlaxoSmithKline LLC
IPC分类号： C07D401/06 , A61K31/47
CPC分类号： C07D471/04
摘要： Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.
-
公开(公告)号：EP2124565B1
公开(公告)日：2015-01-07
申请号：EP08727581.4
申请日：2008-01-11
申请人： GlaxoSmithKline LLC
发明人： SHAW, Antony, N. , DUFFY, Kevin, J. , MILLER, William, Henry , MYERS, Andrea, K. , ZIMMERMAN, Michael, N.
IPC分类号： C07D237/24 , A61K31/50 , A61P7/06 , C07D401/10 , C07D409/04 , C07D417/06
CPC分类号： C07D237/24
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.026 秒)
